Edition:
United States

Peregrine Pharmaceuticals Inc (PPHM.OQ)

PPHM.OQ on NASDAQ Stock Exchange Capital Market

3.15USD
22 Sep 2017
Change (% chg)

$0.03 (+0.96%)
Prev Close
$3.12
Open
$3.13
Day's High
$3.17
Day's Low
$3.12
Volume
42,190
Avg. Vol
57,410
52-wk High
$5.77
52-wk Low
$1.98

Chart for

About

Peregrine Pharmaceuticals, Inc. (Peregrine) is a biopharmaceutical company. The Company operates through two segments: Peregrine, which is engaged in the research and development of monoclonal antibodies for the treatment of cancer, and Avid, which is engaged in providing contract manufacturing services for third party customers... (more)

Overall

Beta: 2.56
Market Cap(Mil.): $142.05
Shares Outstanding(Mil.): 45.10
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.67 16.08
EPS (TTM): -- -- --
ROI: -- 15.12 14.60
ROE: -- 16.35 14.03

BRIEF-Peregrine Pharmaceuticals reports Q1 loss per share $0.06

* Peregrine Pharmaceuticals reports financial results for first quarter of fiscal year 2018 and recent developments

Sep 11 2017

BRIEF-Peregrine Pharma appoints Roger Lias as Avid Bioservices president

* Peregrine Pharmaceuticals announces appointment of Roger J. Lias, PH.D. as president of Avid Bioservices

Sep 11 2017

BRIEF-Peregrine announces measures to reduce costs, facilitate profitability and strengthen its operations

* Peregrine announces measures to reduce costs, facilitate profitability and strengthen its operations

Aug 11 2017

BRIEF-Peregrine ‍says "to evaluate strategic options for advancing research and development business​"

* Peregrine Pharmaceuticals Inc - ‍continues to evaluate strategic options for advancing research and development business​

Jul 31 2017

BRIEF-Ronin Trading, SW Investment Management issue letter to Peregrine Pharma employees​

* ‍Ronin Trading and SW Investment Management say issued a letter to Peregrine Pharmaceuticals' employees​

Jul 20 2017

BRIEF-Peregrine Pharmaceuticals Q4 revenue $17.9 million

* Peregrine Pharmaceuticals reports financial results for quarter and fiscal year ended April 30, 2017 and recent developments

Jul 14 2017

BRIEF-Ronin Trading and SW Investment Management issue letter to stockholders of Peregrine Pharmaceuticals

* Ronin Trading and SW Investment Management issue letter to stockholders of Peregrine Pharmaceuticals

Jul 13 2017

BRIEF-Peregrine Pharmaceuticals presents preliminary correlative analysis of PD-l1 expression from sunrise trial

* Peregrine Pharmaceuticals presents preliminary correlative analysis of pd-l1 expression from sunrise trial at asco 2017

Jun 05 2017

BRIEF-Ronin Capital LLC reports 5.8 pct stake in Peregrine Pharmaceuticals

* Ronin Capital LLC reports 5.8 percent stake in Peregrine Pharmaceuticals Inc as of April 6 - sec filing Source text : http://bit.ly/2prmM8N Further company coverage:

Apr 17 2017

BRIEF-Peregrine Pharma presents data for Bavituximab's anti-tumor enhancing activity

* Peregrine Pharmaceuticals highlights clinical data presentation at aacr 2017 annual meeting supporting potential of Bavituximab to enhance anti-tumor activity of immunotherapy

Apr 04 2017

Competitors

  Price Chg
DAIICHI SANKYO COMPANY, LIMITED (4568.T) ¥2,564 -1.50
HANALL BIOPHARMA (009420.KS) ₩12,300.00 0.00
Pfizer Inc. (PFE.N) $35.96 -0.01
Johnson & Johnson (JNJ.N) $131.39 -0.36
Novartis AG (NOVN.S) CHF83.45 +0.50
Merck & Co., Inc. (MRK.N) $65.13 -0.47
Roche Holding Ltd. (ROG.S) CHF248.00 -1.00
Roche Holding Ltd. (RO.S) CHF248.00 -1.00
Bayer AG (BAYGn.DE) €110.10 -0.30
Bayer AG (BAYE.F) -- --

Earnings vs. Estimates